Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma
Haipeng Zhang(Jinan University), Guangmei Yan(Sun Yat-sen University), Jun Hu(China University of Geosciences), Liwu Fu(Sun Yat-sen University), Jing Cai(Shandong University), Fan Xing(Sun Yat-sen University), Bingzheng Lu(Sun Yat-sen University), Fang Wang(Sun Yat-sen University), Kai Li(China University of Geosciences (Beijing)), Yuan Lin(Sun Yat-sen University), Wei Yin, Shoufang Gong(Regenex Pharmaceuticals (China)), Wenbo Zhu(Sun Yat-sen University), Xuetao Bai(Regenex Pharmaceuticals (China)), Xiao Xiao(Guangdong Academy of Medical Sciences), Xingwen Su(Sun Yat-sen University), Jiankai Liang(Sun Yat-sen University), Pengxin Qiu, Yaqian Tan(Guangzhou Medical University)
Cited by 84
Related Papers
KRAS mutation: from undruggable to druggable in cancer
|Signal Transduction and Targeted Therapy|2021|1k
Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
|Cancer Research|2008|385
Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters
|Cancer Research|2010|348
Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers
|Proceedings of the National Academy of Sciences|2014|167